267 related articles for article (PubMed ID: 28464316)
21. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in stage I non-small cell lung cancer following the introduction of stereotactic body radiotherapy in Alberta - A population-based study.
Liu HW; Gabos Z; Ghosh S; Roberts B; Lau H; Kerba M
Radiother Oncol; 2015 Oct; 117(1):71-6. PubMed ID: 26349589
[TBL] [Abstract][Full Text] [Related]
23. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
26. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
27. Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy.
Tahir I; Marquardt JP; Mercaldo ND; Bourgouin PP; Wrobel MM; Mrah S; Sharp GC; Khandekar MJ; Willers H; Keane FK; Fintelmann FJ
AJR Am J Roentgenol; 2022 Oct; 219(4):579-589. PubMed ID: 35416054
[No Abstract] [Full Text] [Related]
28. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
29. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
[TBL] [Abstract][Full Text] [Related]
30. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence.
van Timmeren JE; van Elmpt W; Leijenaar RTH; Reymen B; Monshouwer R; Bussink J; Paelinck L; Bogaert E; De Wagter C; Elhaseen E; Lievens Y; Hansen O; Brink C; Lambin P
Radiother Oncol; 2019 Jul; 136():78-85. PubMed ID: 31015133
[TBL] [Abstract][Full Text] [Related]
32. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC; Polley MY; Bhave SR; Redler G; Pitroda SP; Luke JJ; Chmura SJ
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):189-195. PubMed ID: 32569799
[TBL] [Abstract][Full Text] [Related]
33. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
35. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC.
Ackerson BG; Tong BC; Hong JC; Gu L; Chino J; Trotter JW; D'Amico TA; Torok JA; Lafata K; Chang C; Kelsey CR
Lung Cancer; 2018 Nov; 125():185-191. PubMed ID: 30429018
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
38. Mortality after radiotherapy or surgery in the treatment of early-stage non-small-cell lung cancer: a population-based data analysis in the clinical cancer registry of Brandenburg-Berlin.
Müller JA; Vordermark D; Medenwald D
Strahlenther Onkol; 2023 Jul; 199(7):658-667. PubMed ID: 36912978
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
[TBL] [Abstract][Full Text] [Related]
40. Pleural contact decreases survival in clinical T1N0M0 lung cancer patients undergoing SBRT.
Eriguchi T; Takeda A; Tsurugai Y; Sanuki N; Kibe Y; Hara Y; Kaneko T; Taguri M; Shigematsu N
Radiother Oncol; 2019 May; 134():191-198. PubMed ID: 31005215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]